Other languages Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Market Closed - Australian S.E. Other stock markets 11:29:38 31/05/2024 am IST			5-day change	1st Jan Change
0.585 ^AUD	+0.86%		-2.50%	+9.35%

17/05	Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial	CI
15/05	Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial	17/05
Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial	17/05
Recce Pharmaceuticals doses highest cohort in phase I/II UTI/Urosepsis trial	17/05
Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial	15/05
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study	13/05
Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study	13/05
Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study	10/05
Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration	08/05
Recce Pharmaceuticals completes global patent portfolio	08/05
Recce Pharmaceuticals Obtains China Patent for Anti-Infectives	07/05
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis	30/04
Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis	30/04
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)	17/04
Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice	17/04
Recce Pharmaceuticals Advances Production of Anti-Infective Medication	16/04
Recce Pharmaceuticals Provides Business Update	10/04
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024	10/04
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives	04/04
Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives	04/04
Recce Pharmaceuticals Secures Israeli Patent for Anti-Infective Medication; Shares Rise 5%	03/04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Other languages

Filters